--- title: 'Associate Director, Publications at Iovance Biotherapeutics' canonical: 'https://feeny.ai/job/associate-director-publications-iovance-biotherapeutics-remote-n7yfas1d4nf5' type: 'job' last_seen: '2026-11-05' --- # Associate Director, Publications at Iovance Biotherapeutics - **Company:** Iovance Biotherapeutics - **Location:** Remote - **Compensation:** $185k–$205k - **Work type:** remote - **Posted:** 2026-10-28 - **Last confirmed live:** 2026-11-05 - **Apply:** https://job-boards.greenhouse.io/iovancebiotherapeutics/jobs/5461821008 ## Job description About Iovance Biotherapeutics, Inc. [Iovance Biotherapeutics](https://www.iovance.com/), Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The [Iovance TIL platform](https://www.iovance.com/our-science/til-platform/) spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit [www.iovance.com](http://www.iovance.com/). Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on [www.iovance.com](http://www.iovance.com/). ## Overview The Associate Director, Publications, is a core member of the medical affairs team and will report to the Director of Publications. This role will support the development and execution of publication plans, for lifileucel and pipeline products. The Associate Director, Publications works closely with various functional areas within the organization to communicate accurate, consistent, and timely information regarding products and therapeutic areas. The Associate Director will work closely with the cross-functional data generation team (Clinical development, HEOR, Biometrics, preclinical and research) and engage with healthcare professional experts and authors. The role will ensure compliance with publication-related policies and procedures. Essential Functions and Responsibilities - Subject matter expert and internal liaison for lifileucel and pipeline products with ability to work independently and lead/ influence cross-functionally. - Support and facilitate comprehensive cross-functional global publication planning, including generation and execution of annual publication plans and presence at scientific congresses, with an understanding of how these activities support the overall business strategy, and including identification and prioritization of regional and local publication needs - Execute publication plans including partnering with agency partners to ensure delivery of accurate and appropriate publications on time, within budget, and adhering to policy - Partner with Scientific Communications and Field Medical leads to support the incorporation of published data into medical materials (e.g., field medical, medical affairs training) - Ensure the publication development process and all materials produced are in compliance with Iovance policy and guidelines including ICMJE, PhRMA, and GPP - Leverage best practices and implement efficient processes to optimize publication efforts across medical affairs - Support the execution and implementation of iEnvision for publications management - Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics. - Perform miscellaneous duties as assigned. Required Education, Skills, and Knowledge - Advanced scientific/clinical degree required (e.g., PharmD, Ph.D., MD) in a science-related field with 10+ years relevant industry experience in medical/scientific publications either in the pharmaceutical industry or related (e.g., medical communication agency) industry preferred - Experience in Cell Therapy or IO required - Experience in the development and medical writing of peer-reviewed publications and congress materials (abstracts, posters, presentations) - Experience with Publication management systems such as Datavision is required - Strong oncology writing experience - Strong HEOR experience required - Experience with publications planning and execution, including literature gap analysis - Excellent communication, organizational, and time management skills - Experience in literature searches, literature evaluation, and drug information and educational concepts Physical Demands and Activities Required The physical demands described here represent those an employee may encounter while performing the essential functions of this job. Reasonable accommodation may be provided to enable individuals to perform these functions. - Ability to remain in a stationary position for extended periods - Ability to move about within an office or remote workspace and exert up to 10 pounds of force occasionally - Visual acuity sufficient for preparing and analyzing data, viewing computer screens, and extensive reading - Repetitive motion involving wrists, hands, and/or fingers - Ability to communicate effectively to exchange information - Ability to engage in analytical, conceptual, and problem‑solving activities in a dynamic business environment Mental: Clear and conceptual thinking ability; excellent judgment, troubleshooting, problem-solving, analysis, and discretion; ability to manage work-related stress; ability to manage multiple priorities simultaneously with a sense of urgency; and ability to meet deadlines Work Environment This job operates in a professional or remote office environment and requires operating standard office equipment and keyboards. #li-remote The annual base salary we reasonably expect to pay is listed. Individual pay decisions depend on various factors, such as primary work location, complexity and responsibility of the role, job duties/requirements, and relevant education, experience and skills. Pay Transparency $185,000—$205,000 USD The statements contained in this document are intended to describe the general nature and level of work being performed by a colleague assigned to this description. They are not intended to constitute a comprehensive list of functions, duties, or local variances. Management retains the discretion to add or to change the duties of the position at any time. Iovance is committed to cultivating and offering a diverse and inclusive work environment. As an equal-opportunity employer, our employees and applicants will be considered without regard to an individual’s race, color, religion, sex, pregnancy, national origin, age, physical and mental disability, marital status, sexual orientation, gender identity, gender expression, genetic information, military and veteran status, and any other characteristic protected by applicable law. If you need assistance or accommodation to apply to one of our opportunities, please contact careers@iovance.com. By voluntarily providing information and clicking “Submit Application”, you explicitly consent to the collection and use of your personal information for the purposes described above and in our [Candidate Privacy Notice](https://www.iovance.com/privacy-policy/). ## About Iovance Biotherapeutics ## Company Overview - **One-liner**: Iovance Biotherapeutics is pioneering tumor infiltrating lymphocyte (TIL) cell therapies to develop personalized, one-time treatments for solid tumor cancers. - **Entity Type**: Public (NASDAQ: IOVA) - **Headquarters**: San Carlos, California, USA - **Founded**: 2007 (originally named Lion Biotechnologies, renamed Iovance Biotherapeutics in 2017) - **Founders**: Not publicly available (the company was formed through a merger and rebranding) ## Core Business - **Primary industry**: Biotechnology — Cell Therapy (Immuno-Oncology) - **Target customers**: B2B / B2G — Healthcare providers, clinical trial sites, and ultimately patients with advanced solid tumors (melanoma, non-small cell lung cancer, endometrial cancer, etc.) - **Mission or purpose statement**: To be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer, harnessing the immune system to recognize and attack diverse cancer cells. ## Products & Services - **Lifileucel (IOV-009)**: A one-time, personalized TIL therapy for advanced melanoma. It is the first approved TIL therapy for a solid tumor (FDA approved in early 2024 under the brand name Amtagvi). - **IOV-LUN-202**: An investigational TIL therapy for advanced non-small cell lung cancer (NSCLC) currently in Phase 2 clinical trials. - **IOV-END-201**: An investigational TIL therapy for advanced endometrial cancer currently in Phase 2 clinical trials. - **IOV-4001**: A next-generation, gene-edited TIL therapy (using TALEN technology to inactivate PD-1 expression) for solid tumors, currently in preclinical/early clinical development. - **IOV-3001**: An engineered IL-2 therapy (licensed from Novartis) designed to support TIL therapy efficacy, currently in preclinical development. - **Cell Therapy Manufacturing (iCTC)**: The company operates a 136,000-square-foot, state-of-the-art Cell Therapy Center in Philadelphia, PA, for proprietary GMP manufacturing of TIL therapies. ## Market Standing - **Valuation/Market Cap**: As of early 2026, market capitalization is approximately $2.5–3.0 billion (fluctuates with FDA news and clinical data). Check current price on NASDAQ: IOVA. - **Key Metric (Revenue)**: Iovance generated its first commercial revenue from Lifileucel/Amtagvi in 2024. Annual revenue for 2025 was approximately $180–220 million (estimate based on analyst reports; exact figure not yet fully disclosed). The company is not yet profitable. - **Key Metric (Funding)**: As a public company, Iovance has raised over $1.5 billion through public offerings and debt financings. Notable recent raise: a public offering in 2022 and subsequent at-the-market offerings. - **Notable Investors/Partners**: - Novartis (license partner for IOV-3001) - Major institutional investors (e.g., BlackRock, Vanguard, and several healthcare-focused funds) - Collaborations with major cancer centers for clinical trials (e.g., MD Anderson, Memorial Sloan Kettering, etc.) - **Growth Signals**: - FDA approval of Lifileucel (Amtagvi) in early 2024 — a landmark first-in-class approval for TIL therapy in solid tumors. - Rapid commercial launch and expansion of treatment centers across the U.S. - Multiple ongoing Phase 2/3 trials in large indications (NSCLC, endometrial cancer, frontline melanoma). - Investment in next-generation gene-edited TIL (IOV-4001) and engineered IL-2 (IOV-3001) to improve efficacy and expand addressable patient populations. ## Competitive Advantages - **First-to-market TIL therapy**: Iovance is the only company with an FDA-approved TIL therapy for a solid tumor (Amtagvi for melanoma), giving it a significant head start in manufacturing, commercial infrastructure, and physician education. - **Proprietary manufacturing platform**: The in-house iCTC facility in Philadelphia enables scalable, standardized GMP production of personalized TIL therapies, a major barrier to entry for competitors. - **Broad solid tumor pipeline**: Unlike CAR-T therapies (primarily effective in blood cancers), TIL therapy has shown promise across multiple solid tumor types, providing a large addressable market. - **Polyclonal T cell approach**: The therapy targets a broad range of neoantigens unique to each patient’s tumor, potentially reducing the risk of immune escape compared to single-target therapies. ## Strategic Focus - **Commercial expansion**: Scaling up the launch of Amtagvi for advanced melanoma and expanding treatment center network globally. - **Pipeline acceleration**: Advancing pivotal trials in NSCLC (IOV-LUN-202) and endometrial cancer (IOV-END-201) to secure additional FDA approvals. - **Next-generation innovation**: Developing gene-edited TIL (IOV-4001) to enhance persistence and efficacy, and engineered IL-2 (IOV-3001) to improve the TIL therapy cycle. - **Manufacturing optimization**: Continuing to improve manufacturing efficiency and turnaround time at the iCTC facility to support growing demand and reduce costs. ## Why Work Here - **Mission-driven culture**: The company is deeply patient-centric, with a clear focus on delivering transformative therapies to cancer patients. Employees often cite the meaningful impact of their work as a key motivator. - **Values**: Integrity, agility, innovation, collaboration, and excellence are core to the company’s operating philosophy. The culture emphasizes transparency, teamwork, and high ethical standards. - **Diversity, Equity, and Inclusion**: Iovance has a stated commitment to DEI, recognizing that internal diversity is critical to serving diverse patient populations and driving innovation. - **Remote/Hybrid policy**: Many roles (especially in clinical, medical affairs, marketing, and commercial functions) are remote or hybrid. Laboratory and manufacturing roles are based on-site in Philadelphia, PA (iCTC) or San Carlos, CA (HQ). - **Benefits**: Competitive salaries, annual cash bonuses, long-term incentives (stock options/RSUs), 401(k) with match, Employee Stock Purchase Plan, comprehensive medical/dental/vision (low employee cost), Health Savings Account contributions, paid parental leave, tuition assistance, wellness program (gym discounts), and professional development opportunities. - **Work environment**: Agile and fast-paced, typical of a biotech company at a critical growth stage. The company values data-driven decision-making and encourages employees to bring their best efforts every day. ## Sources 1. [iovance.com](https://www.iovance.com/) 2. [iovance.com - About Us](https://www.iovance.com/about-iovance-biotherapeutics/) 3. [iovance.com - Culture](https://www.iovance.com/culture/) 4. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/iovancebiotherapeutics) ## Other roles at Iovance Biotherapeutics - [Director, Business Development](https://feeny.ai/job/director-business-development-iovance-biotherapeutics-remote-jqphzedfvvtv) - [Director, Business Development](https://feeny.ai/job/director-business-development-iovance-biotherapeutics-remote-1djn30k8cgq3) - [Commercial Lead, Australia](https://feeny.ai/job/commercial-lead-australia-iovance-biotherapeutics-sydney-new-south-wales-gheerqsw6c76) — Sydney New South Wales, Australia - [Associate Director, R&D and Commercial IT](https://feeny.ai/job/associate-director-r-d-and-commercial-it-iovance-biotherapeutics-remote-75am8yz0smzk) - [Logistics & Planning Associate II](https://feeny.ai/job/logistics-planning-associate-ii-iovance-biotherapeutics-philadelphia-8ttnst936xpm) — Philadelphia, PA - [Supervisor, Aseptic Manufacturing](https://feeny.ai/job/supervisor-aseptic-manufacturing-iovance-biotherapeutics-philadelphia-kb32t68qngpv) — Philadelphia, PA - [Manager, Quality Assurance Operations](https://feeny.ai/job/manager-quality-assurance-operations-iovance-biotherapeutics-philadelphia-5dnbp2p4550d) — Philadelphia, PA - [Manager, US Commercial Analytics](https://feeny.ai/job/manager-us-commercial-analytics-iovance-biotherapeutics-remote-pp175wb1c3rg) - [Scientific Director, Medical Affairs](https://feeny.ai/job/scientific-director-medical-affairs-iovance-biotherapeutics-remote-hw991kwkzz0n) - [Associate Director, Clinical Operations](https://feeny.ai/job/associate-director-clinical-operations-iovance-biotherapeutics-remote-x88j1h7q322y)